Ra Capital Management, L.P. Ascendis Pharma A/S Call Options Transaction History
Ra Capital Management, L.P.
- $7.17 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
244Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Westfield Capital Management CO LP Boston, MA5.13MShares$701 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$681 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$602 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$571 Million0.33% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.12MShares$289 Million0.04% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.62B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...